Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors

References

• BarnesPJKarinMNuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseasesN Engl J Med19973361066719091804
   PubMed Web of Science ®Google Scholar
• Blanco-ColioLMTuñónJMartín-VenturaJLAnti-inflammatory and immunomodulatory effects of statinsKidney Int200363122312472764
   PubMed Web of Science ®Google Scholar
• BonettiPOWilsonSHRodriguez-PorcelMSimvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid loweringJ Am Coll Cardiol2002405465412142124
   PubMed Web of Science ®Google Scholar
• BourcierTLibbyPHMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cellsArterioscler Thromb Vasc Biol2000205566210669656
   PubMed Web of Science ®Google Scholar
• BustosCHernández-PresaMAOrtegoMHMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosisJ Am Coll Cardiol1998322057649857893
   PubMed Web of Science ®Google Scholar
• CerielloAAssaloniRDa RosREffect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patientsCirculation200511125182415867169
   PubMed Web of Science ®Google Scholar
• ChenJLiDSchaeferRCross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis Studies with the combined use of rosuvastatin and candesartanAtherosclerosis200618429530116005008
   PubMed Web of Science ®Google Scholar
• CipolloneFFaziaMIezziABlockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activityCirculation20041091482815037537
   PubMed Web of Science ®Google Scholar
• CorriuCBernardSSchottCEffects of losartan on contractile responses of conductance and resistance arteries from ratsJ Cardiovasc Pharmacol199526688928637181
   PubMed Web of Science ®Google Scholar
• CrabosMBrertschinSBühlerFRIdentification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertensionJ Hypertens Suppl199311S23018158359
   PubMedGoogle Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• DandonaPKumarVAljadaAAngiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory actionJ Clin Endocrinol Metab200388449650112970329
   PubMed Web of Science ®Google Scholar
• DaviGAvernaMCatalanoIIncreased thromboxane biosynthesis in type IIa hypercholesterolemiaCirculation199285179281572035
   PubMed Web of Science ®Google Scholar
• DietFPrattREBerryGJIncreased accumulation of tissue ACE in human atherosclerotic coronary artery diseaseCirculation1996942756678941100
   PubMed Web of Science ®Google Scholar
• EssigMNguyenGPrieD3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteinsCirc Res199883683909758637
   PubMed Web of Science ®Google Scholar
• EtoMKozaiTCosentinoFStatin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathwaysCirculation20021051756911956113
   PubMed Web of Science ®Google Scholar
• FliserDBuchholzKHallerHAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation20041101103715313950
   PubMed Web of Science ®Google Scholar
• GloriosoNTroffaCFilighedduFEffect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemiaHypertension1999341281610601131
   PubMed Web of Science ®Google Scholar
• GrandalianoGBiswasPChoudhuryGGSimvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cellsKidney Int19934450388231022
   PubMed Web of Science ®Google Scholar
• HarrisonDGVenemaRCArnalJFThe endothelial cell nitric oxide synthase: is it really constitutively expressed?Agents Actions Suppl199545107177536382
   PubMedGoogle Scholar
• HeMHeXXieQAngiotensin II induces the expression of tissue factor and its mechanism in human monocytesThromb Res20061175799015953627
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• Hernández-PresaMBustosCOrtegoMAngiotensin Converting enzyme inhibition prevents arterial NF-kB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosisCirculation1997951532419118522
   PubMed Web of Science ®Google Scholar
• Hernández-PresaMABustosCOrtegoMThe ACE inhibitor quinapril reduces the arterial expression of NF-κB dependent proinflammatory factors but not of collagen in a rabbit model of atherosclerosisAm J Pathol19981531825379846973
   PubMed Web of Science ®Google Scholar
• Hernández-PresaMAMartín-VenturaJLOrtegoMAtorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cellsAtherosclerosis2002160495811755922
   PubMed Web of Science ®Google Scholar
• IschiropoulosHAl-MehdiABPeroxynitrite-mediated oxidative protein modificationsFEBS Lett1995364279827758583
   PubMed Web of Science ®Google Scholar
• ItoKIkedaUYamamotoKRegulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cellsAtherosclerosis200216551512208470
   PubMed Web of Science ®Google Scholar
• ItoATsaoPSAdimoolamSNovel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolaseCirculation1999993092510377069
   PubMed Web of Science ®Google Scholar
• IwanciwDRehmMPorstMInduction of connective tissue growth factor by angiotensin II: integration of signaling pathwaysArterioscler Thromb Vasc Biol2003231782712947014
   PubMed Web of Science ®Google Scholar
• JamesIMDickensonEJBurgoyneWTreatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregationJ Hum Hypertens198822153070031
   PubMed Web of Science ®Google Scholar
• KannelWBDawberTRKaganAFactors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham StudyAnn Intern Med196155335013751193
   PubMed Web of Science ®Google Scholar
• KeidarSAttiasJAngiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathwayBiochem Biophys Res Commun19972396379345270
   PubMed Web of Science ®Google Scholar
• KimSIHanDCLeeHBLovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cellsJ Am Soc Nephrol20001180710616843
   PubMed Web of Science ®Google Scholar
• KohKKChungWJAhnJYAngiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled studyAtherosclerosis20041771556015488878
   PubMed Web of Science ®Google Scholar
• LaufsULa FataVPlutzkyJUpregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitorsCirculation1998971129359537338
   PubMed Web of Science ®Google Scholar
• LuanZChaseAJNewbyACStatins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophagesArterioscler Thromb Vasc Biol2003237697512663370
   PubMed Web of Science ®Google Scholar
• LuchtefeldMGroteKGrothusenCAngiotensin II induces MMP-2 in a p47phox-dependent mannerBiochem Biophys Res Commun2005328183815670768
   PubMed Web of Science ®Google Scholar
• ManciniGBHenryGCMacayaCAngiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) StudyCirculation19969425865 Erratum in: Circulation, 1996;94:14908759064
   PubMed Web of Science ®Google Scholar
• Martín-VenturaJLBlanco-ColioLMGómez-HernándezAIntensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one monthStroke200536179680016020773
   PubMed Web of Science ®Google Scholar
• McGillHGFusterVRossRTopolEMajor risk factors and primary prevention: OverviewAtherosclerosis and coronary artery disease1996PhiladelphiaLippincott-Raven2541
   Google Scholar
• MorawietzHRueckschlossUNiemannBAngiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoproteinCirculation199910089990210468518
   PubMed Web of Science ®Google Scholar
• NickenigGBäumerATTemurYStatin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic menCirculation19991002131410571970
   PubMed Web of Science ®Google Scholar
• NickenigGSachinidisAMichaelsenFUpregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cellsCirculation19979547389008466
   PubMed Web of Science ®Google Scholar
• NotarbartoloADaviGAvernaMInhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemiaArterioscler Thromb Vasc Biol199515247517749833
   PubMed Web of Science ®Google Scholar
• O’DriscollGGreenDTaylorRRSimvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 monthCirculation1997951126319054840
   PubMed Web of Science ®Google Scholar
• OrtegoMBustosBHernández-PresaMAAtorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cellsAtherosclerosis1999147253610559511
   PubMed Web of Science ®Google Scholar
• OrtegoMGómez HernándezAVidalCHMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cellsJ Cardiovasc Pharmacol2005454687515821443
   PubMed Web of Science ®Google Scholar
• PoulterNRWedelHDahlofBRole of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Lancet20053669071316154017
   PubMed Web of Science ®Google Scholar
• RajagopalanSKurzSMünzelTAngiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations to vasomotor toneJ Clin Invest1996971916238621776
   PubMed Web of Science ®Google Scholar
• RayKKCannonCPThe potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromesJ Am Coll Cardiol20054614253316226165
   PubMed Web of Science ®Google Scholar
• RiazAAWangYSchrammRRole of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colonFASEB J200418881315001561
   PubMed Web of Science ®Google Scholar
• RobbesynFGarciaVAugeNHDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cellsFASEB J200317743512586748
   PubMed Web of Science ®Google Scholar
• RupérezMLorenzoOBlanco-ColioLMConnective tissue growth factor is a mediator of angiotensin II-induced fibrosisCirculation2003108149950512952842
   PubMed Web of Science ®Google Scholar
• SchiefferBBunteCWitteJComparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery diseaseJ Am Coll Cardiol200444362815261932
   PubMed Web of Science ®Google Scholar
• SchiefferBSchiefferEHilfiker-KleinerDExpression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instabilityCirculation20001011372810736279
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336111495812686036
   PubMed Web of Science ®Google Scholar
• ToschiVGalloRLettinoMTissue factor modulates the thrombogenicity of human atherosclerotic plaquesCirculation19979559499024145
   PubMed Web of Science ®Google Scholar
• TuñónJBarderasMGJiménez–NácherJJAtorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndromeJ Am Coll Cardiol200749Suppl A355A
   Google Scholar
• TuñónJEgidoJEndothelial dysfunction, inflammation and statins: new evidencesRev Esp Cardiol200457903515469785
   PubMed Web of Science ®Google Scholar
• Ushio-FukaiMAlexanderRWAkersMp38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophyJ Biol Chem19982731502299614110
   PubMed Web of Science ®Google Scholar
• VaughanDERouleauJLPfefferMARole of the fibrinolytic system in preventing myocardial infarctionEur Heart J199516Suppl K3168869133
   PubMedGoogle Scholar
• VictorinoGPNewtonCRCurranBEffect of angiotensin II on microvascular permeabilityJ Surg Res2002104778112020123
   PubMed Web of Science ®Google Scholar
• WarnholtzANickenigGSchulzEIncreased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin systemCirculation19999920273310209008
   PubMed Web of Science ®Google Scholar
• WongJRauhoftCDilleyRJAngiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formationCirculation1997961631409315558
   PubMed Web of Science ®Google Scholar
• WrightRAFlapanADAlbertiKGEffects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarctionJ Am Coll Cardiol19942467738006284
   PubMed Web of Science ®Google Scholar
• XuXPMeiselSROngJMOxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophagesCirculation199999993810051290
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med20003421455310639539
   PubMed Web of Science ®Google Scholar